Bio Key International Inc

Name: Bio Key International Inc standardized financial statements, quarterly
Creator: Listed

BKYINasdaqCIK 1019034TechnologyFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.9m, Q2 FY2026

Operating income−$529.4k, Q2 FY2026

Net income−$576.9k, Q2 FY2026

Bio Key International Inc, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	1,817	1,825	2,181	1,141	2,145	1,462	1,607	1,697	1,550	1,084	2,146	1,920
Cost of revenue	$k	1,477	1,921	300	262	465	262	279	464	358	271	376	246
Gross profit	$k	341	(95.5)	1,882	879	1,680	1,200	1,328	1,233	1,192	812	1,769	1,674
Research and development	$k	530	617	608	591	652	660	596	636	684	694	617	640
Selling, general and administrative	$k	1,776	2,040	1,783	1,942	1,608	1,807	1,373	1,681	1,400	1,829	1,310	1,563
Operating income	$k	(1,966)	(2,724)	(509)	(1,654)	(580)	(1,268)	(641)	(1,084)	(892)	(4,211)	(158)	(529)
Interest expense	$k	45.7	58.9	1.4	8.9	98.6	66.9	35.9	25.6	13.2	(13.9)	27.2	27.0
Income tax	$k	(0.2)	(277)	0.0	0.0	0.0	(23.0)	0.0	0.0	0.0	16.5	0.0	0.0
Net income	$k	(1,838)	(2,373)	(510)	(1,667)	(739)	(1,384)	(737)	(1,167)	(965)	(4,289)	(205)	(577)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	(3.22)	not reported	(0.32)	(1.00)	(0.39)	not reported	(1.57)	(2.01)	(0.15)	not reported	(0.20)	(0.56)

Balance sheet

Cash and equivalents$1.4m, Q2 FY2026

Long-term debt$0, Q2 FY2025

Shareholders' equity$4.3m, Q2 FY2026

Bio Key International Inc, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.3	0.5	0.7	1.3	1.8	0.4	3.1	2.3	2.0	2.7	2.2	1.4
Current assets	$m	4.0	2.6	2.3	3.0	4.6	1.9	4.6	4.0	3.7	4.5	4.5	3.8
Total assets	$m	9.7	4.5	4.2	4.8	6.4	8.6	11.2	10.5	10.1	8.3	8.2	7.5
Current liabilities	$m	6.0	3.2	3.3	5.6	5.9	4.6	3.5	3.5	3.0	3.1	3.2	3.0
Total liabilities	$m	6.4	3.5	3.6	5.9	6.3	4.8	3.7	3.7	4.1	3.2	3.3	3.1
Long-term debt	$m	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0	not reported	not reported	not reported	not reported
Current portion of debt	$m	0.1	0.1	0.1	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	2.3	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(0.5)	1.1	0.5	(1.1)	0.1	3.8	7.5	6.9	6.0	5.1	4.9	4.3

Cash flow

Operating cash flow−$845.7k, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Bio Key International Inc, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(167)	(1,532)	297	(1,421)	(1,276)	(515)	(835)	(880)	(1,123)	(1,831)	(358)	(846)
Capital expenditure	$k	0.0	1.0	1.9	0.0	21.2	(10.0)	4.6	1.5	1.3	4.6	0.0	0.0
Dividends paid	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)81.47m, Q1 FY2013

Bio Key International Inc, shares, quarterly
Line item	Unit	period not labelled2010-06-30	period not labelled2011-03-31	Q2 FY20112011-06-30	Q1 FY20122012-03-31	Q2 FY20122012-06-30	Q1 FY20132013-03-31
Diluted shares (weighted)	m shares	91.0	78.7	78.2	78.2	78.2	81.5

Shares outstanding: 1.44m at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.